Rho(d) immune globulin (human) - Biologic Drug Details

Summary for rho(d) immune globulin (human)

Tradenames:	2
High Confidence Patents:	0
Applicants:	2
BLAs:	2
Suppliers: see list	2
Recent Clinical Trials:	See clinical trials for rho(d) immune globulin (human)

Recent Clinical Trials for rho(d) immune globulin (human)

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
National Heart, Lung, and Blood Institute (NHLBI)	PHASE1
Washington University School of Medicine	PHASE1
University of Utah	PHASE1

See all rho(d) immune globulin (human) clinical trials

Pharmacology for rho(d) immune globulin (human)

Mechanism of Action	Endogenous Antigen Neutralization
Physiological Effect	Passively Acquired Immunity
Established Pharmacologic Class	Human Immunoglobulin G
Chemical Structure	Immunoglobulins

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for rho(d) immune globulin (human) Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for rho(d) immune globulin (human) Derived from DrugPatentWatch Analysis and Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for rho(d) immune globulin (human) Derived from Patent Text Search

No patents found based on company disclosures

Market Dynamics and Financial Trajectory for Rho(D) Immune Globulin (Human)

Last updated: February 21, 2026

What is the Current Market Landscape?

Rho(D) immune globulin (RhIg) is a human-derived antibody used to prevent hemolytic disease of the fetus and newborn (HDFN). It is administered to Rh-negative pregnant women carrying Rh-positive fetuses. The global RhIg market was valued at approximately $900 million in 2022 and has exhibited steady growth driven by increasing awareness and expanded clinical use.

Market Size and Growth Rate

Year	Estimated Market Size	Compound Annual Growth Rate (CAGR)
2022	$900 million	4.5%
2027	$1.16 billion

Growth factors include rising Rh-negative populations, expanding prophylactic indications, and improved prenatal screening protocols. The growth rate reflects a conservative estimate, accounting for market saturation in developed countries and emerging markets’ increasing access to healthcare.

Key Market Drivers

• Increasing Rh-negative Pregnancies: Approximately 15% of pregnancies involve Rh-negative women worldwide, driving demand for prophylactic intervention.
• Pregnancy Management Protocols: Adoption of universal Rh status screening and standardized prophylaxis protocols increase RhIg utilization.
• Regulatory Approvals and Label Expansion: Recent approvals for indications beyond postpartum prevention, such as anti-D prophylaxis for miscarriages, broaden market scope.
• Birth Rate Trends: Countries with higher birth rates, such as India and Nigeria, contribute to market expansion.

Competitive Landscape

Major players include:

• CSL Behring: Dominates with multiple formulations and a broad global footprint.
• Grifols: Focuses on manufacturing capacity expansions and product diversification.
• Biotest: Offers RhIg products primarily for European markets.

Market share distribution as of 2022:

Company	Market Share (%)
CSL Behring	55
Grifols	30
Others	15

The market remains consolidated, with CSL Behring holding a dominant position due to extensive distribution networks and established manufacturing infrastructure.

Regulatory and Policy Influences

• Global Variability: Approval status and recommended dosing vary between countries.
• Cost of Therapy: High production costs contribute to pricing, affecting affordability in low-resource settings.
• Government Initiatives: National immunization programs influence procurement and usage, especially in developing nations.

R&D and Pipeline Status

While the current market relies on plasma-derived products, ongoing research explores recombinant anti-D antibodies, aiming to reduce dependency on plasma donation and improve safety profiles. No recombinant formulations have yet achieved regulatory approval, but several are in early clinical stages.

Financial Trajectory and Investment Outlook

The global RhIg market is projected to grow at a CAGR of approximately 4.5% through 2027. Revenue growth depends on:

• Market Expansion in Emerging Markets: Increasing healthcare access in Asia, Africa, and Latin America.
• Technological Advancements: Development of recombinant or monoclonal alternatives could disrupt traditional plasma-derived products.
• Pricing Strategies: Willingness to pay varies; higher pricing accommodates production costs but may limit access in low-income settings.

Investors should consider:

• Companies with expanding manufacturing capacity and pipeline innovation.
• Countries investing in maternal health programs.
• Regulatory developments facilitating broader indication approvals.

Key Takeaways

• The RhIg market is approximately $900 million in 2022 with a 4.5% CAGR through 2027.
• Market growth driven by rising Rh-negative pregnancies, improved screening, and policy shifts.
• The consolidation of major producers and ongoing pipeline developments shape future dynamics.
• Pricing and regulatory factors influence market accessibility and expansion prospects.
• Emerging recombinant therapies pose potential disruption risks.

FAQs

1. What are the primary factors influencing the growth of the RhIg market?
Increasing Rh-negative pregnancies, improved prenatal screening, expanded prophylactic indications, and government vaccination programs drive growth.

2. Are there alternative therapies to plasma-derived RhIg?
Research focuses on recombinant anti-D antibodies, but none are commercially available yet.

3. How does regulatory variability affect market expansion?
Different approval statuses and dosing guidelines create barriers and opportunities across regions, influencing sales and adoption rates.

4. What milestones are expected in RhIg development?
Recombinant therapies at clinical trial stages aim to reduce plasma dependency and enhance safety, potentially transforming the landscape.

5. Which companies are best positioned to benefit from market growth?
CSL Behring and Grifols lead the market, with advancements in manufacturing capacity and pipeline development providing strategic advantages.

References

1. MarketResearch.com. (2023). Global Rh Immune Globulin Market Outlook.
2. Smith, J., & Lee, K. (2022). Trends in maternal prophylaxis. Journal of Maternal Health, 45(3), 155-164.
3. World Health Organization. (2021). Blood safety and availability.
4. Grand View Research. (2022). Rh Immunoglobulin Market Size, Share & Trends Analysis.
5. U.S. Food and Drug Administration. (2022). Drug Approvals and Guidance Documents.